Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC-5214 as adjunct to SSRI/SNRI in major depressive disorder with inadequate response
2010-020140-36Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing TC-5214 adjunct arm with Placebo adjunct arm (2 arms). Primary endpoint: Primary efficacy endpoint. Started Jun 2010; status: completed.
02
Drugs
dexmecamylamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2010-020140-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020140-36.